Lilly's R&D reshuffle: what the large pharma has taken in and dropped
The review of Lilly's dealmaking comes as its weight-loss franchise pushes the stock toward record highs and attention shifts to hair loss assets.
Read at Pharma Voice โFull coverage ยท 4 outlets
- Pharma Voice ยท lead
- ์์์๊ฒฝ์ After Obesity, Is Hair Loss Next? Eli Lilly's Investment and Acquisition Moves in Focus [Click e-Stock]
- TheStreetUnprecedented weight-loss drug craze pushing Lilly to near-record highs
- 36KrByteDance, Baidu, Hengrui & Novo Nordisk: Driving Breakthroughs in AI Pharmaceutical Commercialization